London, UK -- (MARKET WIRE) -- April 18, 2007 --

LONDON, UK, APRIL 18, 2007-- SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) announces that a Circular containing details of a new long-term incentive plan (the "LTIP") will today be posted to shareholders.

The Circular includes a notice convening an Extraordinary General Meeting to be held at 11.00 a.m. on 4 May 2007 at the offices of Fasken Martineau Stringer Saul LLP, 4th Floor, 17 Hanover Square, London, W1S 1HU at which a resolution will be proposed to approve the LTIP.

For further information please contact:

SkyePharma PLC                                     +44 207 491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director

Financial Dynamics                                 +44 207 7831 3113
David Yates
Deborah Scott

The Trout Group                                    + 1 617 583 1308
Seth Lewis

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has nine approved products in the areas of oral, inhalation and topical delivery that are marketed throughout the world by leading pharmaceutical companies. For more information, visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange